Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms

No abstract is available for this paper.

• Publication year

  2007

• Venue

  European Archives of Psychiatry and Clinical Neuroscience

• Publication date

  2007-07-14

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1007/s00406-007-0739-xPMID 17629731
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Quetiapine is no less effective than risperidone for reducing symptoms of schizophrenia

  2007cited by this paper
• Neurocognitive functioning in patients with first-episode schizophrenia

  2006cited by this paper
• The NIMH-MATRICS consensus statement on negative symptoms.

  2006cited by this paper
• One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia.

  2006cited by this paper
• Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study.

  2006cited by this paper
• Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review.

  2006cited by this paper
• Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis.

  2006cited by this paper
• Improvement in social competence with short-term atypical antipsychotic treatment: a randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning.

  2006cited by this paper
• Cognitive functioning in the early course of first-episode schizophrenia spectrum disorders

  2006cited by this paper
• Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms

  2005cited by this paper
• Cognitive Improvement in Schizophrenic Patients does not Require a Serotonergic Mechanism: Randomized Controlled Trial of Olanzapine vs Amisulpride

  2005cited by this paper
• Treatment of cognitive dysfunction in schizophrenia.

  2005cited by this paper
• Correlates of cognitive deficits in first episode schizophrenia.

  2004cited by this paper
• Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior.

  2004cited by this paper
• Neurocognition and long-term prediction of quality of life in outpatients with severe and persistent mental illness.

  2004cited by this paper
• Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.

  2004cited by this paper
• Cognitive Factors in Schizophrenia: Causes, Impact, and Treatment

  2004cited by this paper
• Early treatment-induced improvement of negative symptoms predicts cognitive functioning in treatment-naive first episode schizophrenia: a 2-year followup.

  2004cited by this paper
• Should cognitive deficit be a diagnostic criterion for schizophrenia?

  2004cited by this paper
• New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis.

  2003cited by this paper
• The effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings.

  2003cited by this paper
• The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone.

  2002cited by this paper
• Symptom patterns and subgrouping of schizophrenic patients: significance of negative symptoms assessed on admission.

  2002cited by this paper
• Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.

  2002cited by this paper
• Efficacy, safety, and tolerability of quetiapine in patients with schizophrenia.

  2002cited by this paper
• Atypical, but Not Typical, Antipsychotic Drugs Increase Cortical Acetylcholine Release without an Effect in the Nucleus Accumbens or Striatum

  2002cited by this paper
• Dementia praecox and paraphrenia

  2002cited by this paper
• A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study.

  2001cited by this paper
• Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.

  2001cited by this paper
• Stability and course of neuropsychological deficits in schizophrenia.

  2001cited by this paper
• Atypical antipsychotics: are some more atypical than others?

  2000cited by this paper
• Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?

  2000cited by this paper
• Do specific neurocognitive deficits predict specific domains of community function in schizophrenia?

  2000cited by this paper
• Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action.

  2000cited by this paper
• Development, disease and degeneration in schizophrenia: a unitary pathophysiological model.

  1999cited by this paper
• Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials.

  1999cited by this paper
• Memory deficits in patients with schizophrenia: preliminary data from the Wechsler Memory Scale-Third Edition support earlier findings.

  1999cited by this paper
• The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis.

  1999cited by this paper
• Should schizophrenia be treated as a neurocognitive disorder?

  1999cited by this paper
• Treatment of schizophrenia

  1999cited by this paper
• Dopamine- and serotonin-receptors in schizophrenia: results of imaging-studies and implications for pharmacotherapy in schizophrenia

  1999cited by this paper
• The role of negative symptoms and cognitive dysfunction in schizophrenia outcome

  1998cited by this paper
• A comparison of clustering solutions for cognitive heterogeneity in schizophrenia

  1998cited by this paper
• Differential relationships between positive and negative symptoms and neuropsychological deficits in schizophrenia.

  1997cited by this paper
• Social-Adaptive Functioning Evaluation (SAFE): a rating scale for geriatric psychiatric patients.

  1997cited by this paper
• Neurocognitive Correlates of Positive and Negative Syndromes in Schizophrenia

  1997cited by this paper
• Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group.

  1997cited by this paper
• Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia.

  1997cited by this paper
• Cognition, negative symptoms, and diagnosis: a comparison of schizophrenic, bipolar, and control samples.

  1997cited by this paper
• Is it possible to be schizophrenic yet neuropsychologically normal?

  1997cited by this paper
• Does risperidone improve verbal working memory in treatment-resistant schizophrenia?

  1997cited by this paper
• The functional significance of symptomatology and cognitive function in schizophrenia.

  1997cited by this paper
• What are the functional consequences of neurocognitive deficits in schizophrenia?

  1996cited by this paper
• Olanzapine versus Placebo and Haloperidol

  1996cited by this paper
• Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.

  1996cited by this paper
• Cognitive Function in Schizophrenia: Association with Negative and Positive Symptoms

  1996cited by this paper
• Neurocognitive deficits and social functioning in outpatients with schizophrenia.

  1996cited by this paper
• Auditory working memory and the Wisconsin card sorting test

  1995cited by this paper
• The negative component in schizophrenia

  1995cited by this paper
• A pen-and-paper human analogue of a monkey prefrontal cortex activation task: spatial working memory in patients with schizophrenia.

  1995cited by this paper
• Effects of Risperidone in Tardive Dyskinesia: An Analysis of the Canadian Multicenter Risperidone Study*

  1995cited by this paper
• Risperidone in the treatment of negative symptoms of schizophrenia: a meta‐analysis

  1995cited by this paper
• Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome.

  1994cited by this paper
• The Effect of Clozapine on Cognition and Psychiatric Symptoms in Patients with Schizophrenia

  1993cited by this paper
• Cognitive functioning and positive and negative symptoms in schizophrenia.

  1991cited by this paper
• Natural history of schizophrenia subtypes. II. Positive and negative symptoms and long-term course.

  1991cited by this paper
• Neuere Ansätze zur Diagnostik und Therapie schizophrener Minussymptomatik

  1990cited by this paper
• Minussymptomatik und kognitive Basissymptome

  1990cited by this paper
• Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia.

  1989cited by this paper
• Anticholinergic Effects on Memory: Benztropine versus Amantadine

  1989cited by this paper
• Coding and recall of categorized material in aphasics.

  1989cited by this paper
• Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

  1988cited by this paper
• Positive and negative symptoms in schizophrenia: attentional performance correlates.

  1986cited by this paper
• COMPARATIVE STUDIES OF SOME PSYCHOLOGICAL TESTS FOR CEREBRAL DAMAGE

  1965cited by this paper
• L’examen Clinique en Psychologie

  1959cited by this paper
• Validity of the Trail Making Test as an Indicator of Organic Brain Damage

  1958cited by this paper

• Impact of selected second and third generation antipsychotics on cognitive dysfunction in schizophrenia-spectrum disorders. Systematic review and network meta-analysis.

  2025cites this paper
• Quetiapine treatment corrects behavioral impairments and promotes neuroplasticity in a neurodevelopmental rat model of schizophrenia.

  2025cites this paper
• Comparative efficacy and safety of Clozapine vs. Quetiapine in schizophrenia and related disorders: An updated systematic review.

  2025cites this paper
• The Effect of Antipsychotics on Cognition in Schizophrenia—A Current Narrative Review

  2024cites this paper
• Quetiapine Moderates Doxorubicin-Induced Cognitive Deficits: Influence of Oxidative Stress, Neuroinflammation, and Cellular Apoptosis

  2023cites this paper
• Adverse effects of antipsychotics on sleep in patients with schizophrenia. Systematic review and meta-analysis

  2023cites this paper
• Long-lasting rescue of schizophrenia-relevant cognitive impairments via risperidone-loaded microPlates

  2022cites this paper
• Prospects for Neurotrophic Factor-Based Early Intervention in Schizophrenia: Lessons Learned from the Effects of Antipsychotic Drugs on Cognition, Neurogenesis, and Neurotrophic Factors.

  2022cites this paper
• Role of Tumor Necrosis Factor-Alpha in Schizophrenia and Cognitive Impairment

  2021cites this paper
• Resveratrol Reverses Social Deficits and Metabolic Dysfunction of Mice Model for Negative Symptoms of Schizophrenia

  2021cites this paper
• Title: The Effect of Antipsychotics on the Cognitive Performance of Individuals with Psychotic Disorders: Network Meta-Analyses of Randomized Controlled Trials.

  2021cites this paper
• Japanese Society of Neuropsychopharmacology: “Guideline for Pharmacological Therapy of Schizophrenia”

  2021cites this paper
• A randomized clinical trial of the therapeutic effect of Transcranial direct current stimulation on working Memory in recent-0nset Schizophrenia

  2020cites this paper
• Transcranial direct current stimulation and working memory: Comparison of effect on learning shapes and English letters

  2020cites this paper
• Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia

  2018cites this paper
• Anticholinergic discontinuation and cognitive functions in patients with schizophrenia: a pharmacist–physician collaboration in the outpatient department

  2018cites this paper
• Comparing the effect of the subcategories of atypical antipsychotic medications on cognition in schizophrenia using a meta-analytic approach

  2018cites this paper
• Associations of NEUROD2 polymorphisms and change of cognitive dysfunctions in schizophrenia and schizoaffective disorder after eight weeks of antipsychotic treatment

  2017cites this paper
• Reversal of schizophrenia-like symptoms and immune alterations in mice by immunomodulatory drugs.

  2017cites this paper
• Bilateral Transcranial Direct-current Stimulation (tDCS) of DorsolateralPrefrontal Cortex during Specific Working Memory Tasks

  2016cites this paper
• Second‐generation antipsychotic effect on cognition in patients with schizophrenia—a meta‐analysis of randomized clinical trials

  2015cites this paper
• Antipsychotic-induced parkinsonism is associated with working memory deficits in schizophrenia-spectrum disorders

  2015cites this paper
• Role of quetiapine beyond its clinical efficacy in bipolar disorder: From neuroprotection to the treatment of psychiatric disorders (Review)

  2015cites this paper
• Response to: A Commentary on “Antipsychotic-Induced Parkinsonism is Associated with Working Memory Deficits in Schizophrenia-Spectrum Disorders”

  2015influential citation
• Pharmacokinetics and Tolerability of Extended-Release Quetiapine Fumarate in Han Chinese Patients with Schizophrenia

  2014cites this paper
• Quetiapine and flupentixol differentially improve anterior cingulate cortex function in schizophrenia patients: an event-related potential study.

  2013cites this paper
• Quetiapine versus other atypical antipsychotics for schizophrenia.

  2013cites this paper
• Neurocognitive effectiveness of quetiapine, olanzapine, risperidone, and ziprasidone: A pragmatic, randomized trial☆

  2013cites this paper
• Therapeutic effects of cerebrolysin added to risperidone in patients with schizophrenia dominated by negative symptoms

  2012cites this paper
• Prominent Clinical Dimension, Duration of Illness and Treatment Response in Schizophrenia: A Naturalistic Study

  2012cites this paper
• Changes in cognitive function associated with syndrome changes on two five‐factor models of the Positive and Negative Syndrome Scale

  2012cites this paper
• negative symptoms Therapeutic effects of cerebrolysin added to risperidone in patients with schizophrenia dominated

  2012cites this paper
• Cognitive Efficacy of Quetiapine in Early-Onset First-Episode Psychosis: A 12-Week Open Label Trial

  2012cites this paper
• Improving working memory: the effect of combining cognitive activity and anodal transcranial direct current stimulation to the left dorsolateral prefrontal cortex.

  2011cites this paper
• Driving Ability under Sertindole

  2011cites this paper
• Quetiapine versus other atypical antipsychotics for schizophrenia.

  2010cites this paper
• Evaluation of the clinical efficacy of asenapine in schizophrenia

  2010cites this paper
• Kognitive Störungen bei Schizophrenie und ihre Therapie

  2010cites this paper
• The switch from conventional to atypical antipsychotic treatment should not be based exclusively on the presence of cognitive deficits. A pilot study in individuals with schizophrenia

  2010cites this paper
• Risperidone and haloperidol promote survival of stem cells in the rat hippocampus

  2010cites this paper
• Clozapine versus other atypical antipsychotics for schizophrenia.

  2010cites this paper
• Olanzapine versus other atypical antipsychotics for schizophrenia.

  2010cites this paper
• Neurocognition and its influencing factors in the treatment of schizophrenia—effects of aripiprazole, olanzapine, quetiapine and risperidone

  2010cites this paper
• Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: a mixed treatment comparison of randomized controlled trials.

  2009cites this paper
• Effect of Aripiprazole on Cognition in the Treatment of Patients with Schizophrenia

  2009cites this paper
• [Methodological approaches to assessment of negative symptoms during pharmacotherapy of schizophrenia].

  2009cites this paper
• Umfrage zu Verordnungsgewohnheiten von Psychopharmaka an deutschen psychiatrischen Versorgungskrankenhäusern - Ergebnisse zu Antipsychotika

  2009cites this paper
• Driving simulator performance and psychomotor functions of schizophrenic patients treated with antipsychotics

  2009cites this paper
• Kognitive Störungen bei schizophrenen Patienten

  2009cites this paper
• Binocular depth inversion as a paradigm of reduced visual information processing in prodromal state, antipsychotic-naïve and treated schizophrenia

  2009cites this paper
• Heritability of Trail Making Test performance in multiplex schizophrenia families: implications for the search for an endophenotype

  2009cites this paper
• Current awareness in human psychopharmacology

  2008cites this paper
• Changes in neuropsychological functioning following treatment with risperidone, olanzapine, and conventional antipsychotic medications

  2008cites this paper
• Effectiveness and tolerability of warm-supplementing kidney yang added to risperidone in improving cognitive impairment in patients with schizophrenia: An 8-week, multicenter, randomized, double-blind, placebo-controlled clinical trial.

  2008cites this paper
• Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.

  2008cites this paper
• Associations of SNAP-25 polymorphisms with cognitive dysfunctions in Caucasian patients with schizophrenia during a brief trail of treatment with atypical antipsychotics

  2008influential citation
• [Cognitive changes in response to antipsychotic medication: design and interpretation problems].

  2008cites this paper
• Quetiapine in the treatment of schizophrenia and related disorders

  2007cites this paper
• Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia

  2007cites this paper